| Name | Title | Contact Details |
|---|
BiomedAIliance is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EntreMed is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.
AmpliMed Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.